Clinical trials: RhA - Rheumatoid Arthritis
Rheumatoid Arthritis
Rheumatoid Arthritis DMARD Intervention and UtilizationStudy
To systematically collect and document use patterns, effectiveness and safety of DMARD treatments currently used in the management of rheumatoid arthritis.
- Trial name
- NCT00116727
- Testing
- ENBREL®
- Volunteers
- 5,103 people
- Sponsor
- Amgen
Rheumatoid Arthritis
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
The purpose of this study is to assess the impact of JNJ-38518168 on rheumatoid arthritis (RA) disease-related biomarkers in synovial biopsy tissue and blood in participants with active RA despite methotrexate (MTX) therapy and…
- Trial name
- NCT01862224
- Testing
- JNJ-38518168, Methotrexate
- Where
- 2 sites in United States, Moldova
- Volunteers
- 21 people
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis
ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate
This study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of ACP-196 in subjects with Rheumatoid Arthritis on background Methotrexate.
- Trial name
- NCT02387762
- Testing
- acalabrutinib
- Where
- 17 sites in United States
- Volunteers
- 31 people
- Sponsor
- Acerta Pharma BV
Rheumatoid Arthritis
Long Term Open Label Continuation Study
The purpose of the study was to assess the long-term safety and clinical efficacy following repeated administration of adalimumab in patients with rheumatoid arthritis.
- Trial name
- NCT00195650
- Testing
- Adalimumab
- Where
- 92 sites in United States, Canada
- Volunteers
- 846 people
- Sponsor
- Abbott
Rheumatoid Arthritis
Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route
This is a randomised, double-blind, single dose, parallel groups study to compare the PK, immunogenicity, and safety of 3 abatacept products (DRL_AB, RP and RMP) in male NHV.
- Trial name
- NCT06126042
- Testing
- Test Product, Reference product, Reference Medicinal Product
- Where
- 3 sites in United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Rheumatoid Arthritis
Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects
The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics, and pharmacodynamics following single and multiple ascending oral doses of BMS-986195 in healthy subjects, and to assess the relative…
- Trial name
- NCT02705989
- Testing
- BMS-986195
- Where
- Australia
- Volunteers
- 439 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis
This 4 arm study will compare the safety and efficacy, with regard to reduction of signs and symptoms, of P38 Inhibitor (4) (50, 150 or 300mg po qd) monotherapy versus methotrexate monotherapy in adult patients with active…
- Trial name
- NCT00303563
- Testing
- P38 Inhibitor (4)
- Where
- 61 sites in United States, Canada and 10 more
- Volunteers
- 204 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
The purpose of this study is to determine if abatacept is effective in the treatment of early rheumatoid arthritis.
- Trial name
- AVERT-2 (NCT02504268)
- Testing
- Abatacept, Methotrexate
- Where
- 201 sites in United States, Argentina and 29 more
- Volunteers
- 994 people
- Sponsor
- Bristol-Myers Squibb
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Rheumatoid Arthritis, Ankylosing Spondylitis
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
The aim of this post-marketing observational study is to obtain further data on the evaluation of quality of life outcomes of HUMIRA® in routine clinical use in patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT01083693
- Where
- 20 sites in Austria
- Volunteers
- 162 people
- Sponsor
- Abbott
Rheumatoid Arthritis
A Study Comparing CRx-102 Plus Disease-modifying Anti-rheumatic Drug (DMARD) Therapy to Placebo Plus DMARD Therapy in RA
This study was a Multicenter, Randomized, Blinded Study Comparing the Effect of CRx-102 Plus DMARD Therapy to that of Placebo Plus DMARD Therapy on Serum C Reactive Protein (CRP) and Cytokines in Subjects with Rheumatoid…
- Trial name
- NCT00747214
- Testing
- CRx-102, DMARD Therapy
- Volunteers
- 59 people
- Sponsor
- Zalicus
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.
This single arm study will evaluate the safety and efficacy of MabThera in patients with active rheumatoid arthritis who are receiving methotrexate treatment, and who have had an inadequate response to one anti-TNF alpha therapy.
- Trial name
- NCT00576433
- Testing
- Methotrexate, rituximab [MabThera/Rituxan]
- Where
- 18 sites in Russia
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study
Database analysis: To describe how Orencia is prescribed in France in Rheumatoid Arthritis (RA) To describe joint population of Orencia To assess the impact of the treatment on health status of the treated population as assessed…
- Trial name
- NCT01694693
- Testing
- Orencia
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients
This trial will test the hypothesis that the addition of CF101, a novel anti-inflammatory agent, will improve the clinical condition of patients with rheumatoid arthritis who still have active joint inflammation despite taking…
- Trial name
- NCT00280917
- Testing
- CF101
- Where
- 35 sites in United States, Bulgaria and 5 more
- Volunteers
- 254 people
- Sponsor
- Can-Fite BioPharma
Rheumatoid Arthritis
Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)
The purpose of this study is to evaluate the safety of an additional 28 weeks of treatment with pegsunercept for subjects who have completed treatment in a previous double-blind study (20000201 or 20000198).
- Trial name
- NCT00111423
- Testing
- Pegsunercept (PEG sTNF-RI)
- Volunteers
- 216 people
- Sponsor
- Amgen
Rheumatoid Arthritis
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)
This is a two part study comparing CHS-0214 to Enbrel in patients with active rheumatoid arthritis and an inadequate response with Methotrexate (MTX) who are naive to biologic therapies.
- Trial name
- CHS-0214-02 (NCT02115750)
- Testing
- Etanercept, CHS-0214
- Where
- 141 sites in United States, Belarus and 10 more
- Volunteers
- 647 people
- Sponsor
- Coherus Oncology, Inc.
Rheumatoid Arthritis
Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis
Demonstrate equivalent efficacy of GP2015 and EU-authorized Enbrel in patients with moderate to severe, active (RA) who had an inadequate response to disease modifying anti-rheumatic drugs (DMARD) including methotrexate (MTX).
- Trial name
- EQUIRA (NCT02638259)
- Testing
- GP2015
- Where
- 92 sites in United States, Bulgaria and 14 more
- Volunteers
- 376 people
- Sponsor
- Sandoz
Moderate and Severe RheumatoId Arthritis
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.
The purpose of this study is to initially access the safety and effectivity of RC18 combined with methotrexate (MTX) in comparison with the use of methotrexate alone in participants with moderate to severe Rheumatoid Arthritis…
- Trial name
- NCT03016013
- Testing
- RC18 160 mg plus MTX
- Where
- China
- Volunteers
- 479 people
- Sponsor
- RemeGen Co., Ltd.
Rheumatoid Arthritis
Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)
This Phase 3, randomized, open-label, multicenter study in rheumatoid arthritis (RA) patients with low disease activity (Disease Activity Score 28 [DAS28] >2.8 and <3.5) is being conducted to evaluate induction of remission by…
- Trial name
- NCT00521924
- Testing
- infliximab, DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.
- Volunteers
- 8 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
Efficacy Study of MM-093 in Rheumatoid Arthritis Patients on Methotrexate (MTX)
The purpose of this clinical study is to see if an experimental drug, called MM-093, is safe and effective in the treatment of rheumatoid arthritis.
- Trial name
- NCT00105976
- Testing
- MM-093
- Where
- 38 sites in United States
- Volunteers
- 260 people
- Sponsor
- Merrimack Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.